CytomX Therapeutics, Inc.
Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.
CTMX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US23284F1057
- LEI:
- Country:
- United States of America
- Address:
- 151 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
- Website:
- https://cytomx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing a novel class of investigational antibody therapeutics. The company's core technology is its proprietary Probody® platform, which is designed to create conditionally activated biologics. These therapeutics remain masked and inactive in healthy tissue but are activated specifically within the tumor microenvironment. This approach aims to enhance the therapeutic window, enabling more potent and targeted anti-cancer treatments with potentially reduced toxicity. CytomX is advancing a deep pipeline of Probody therapeutics, both independently and through strategic collaborations, to bring new treatment options to cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CytomX Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CytomX Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CytomX Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
